AACR 2020 — SCLC: second-line camrelizumab-apatinib shows activity


  • Deepa Koli
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Second-line camrelizumab plus apatinib showed potent antitumor activity in patients with extensive-stage small cell lung cancer (SCLC) with acceptable toxicity profile. 

Why this matters

  • Current standard in this setting has low response rate and short duration of response.

Study design

  • The 3-parallel-cohort, phase 2 PASSION trial.
  • 18 patients with extensive-stage SCLC were randomly assigned (1:1:1; stage 1) to receive intravenous camrelizumab every 2 weeks with oral apatinib either once daily (QD), 5 days on/2 days off, or 7 days on/7 days off.
  • The QD cohort was expanded to 47 patients in stage 2.
  • Funding: Jiangsu Hengrui Medicine Co. Ltd.

Key results

  • The overall response rate (ORR) was 34.0% in the QD cohort and 33.3% in the other 2 cohorts.
  • In the QD cohort:
    • ORR: 34.0%.
    • OS: 8.4 months.
    • PFS: 3.6 months.
  • In chemo-sensitive and chemo-resistant patients (disease relapse in ≥90 and ˂90 days after platinum-based chemotherapy, respectively), no difference was seen in:
    • ORR (37.5% vs 32.3%); 
    • median PFS (3.6 vs 2.7 months); and
    • median OS (9.6 vs 8.0 months).
  • Grade ≥3 treatment-related adverse event rate was 72.9%; most common were hypertension (25.4%), hand-foot syndrome (13.6%), and decreased platelet count (13.6%).
  • Toxicity-related discontinuation rate: 8.4%.
  • No treatment-related death was reported.

Limitations

  • Open-label, no comparator.

Since AACR 2020 is a virtual meeting, registered users can watch this session and all presentations online.